L 659699Alternative Names: 1233A; F 244
Latest Information Update: 15 Feb 1995
At a glance
- Originator Merck & Co
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol synthesis inhibitors; HMG-CoA reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 15 Feb 1995 Discontinued-Preclinical for Hypercholesterolaemia in USA (Unknown route)